Summit Therapeutics (SMMT) Depreciation & Amortization (CF) (2020 - 2026)
Summit Therapeutics (SMMT) posted Depreciation & Amortization (CF) of $44000.0 for Q1 2026, up 4.76% on a QoQ basis from $42000.0 in Q4 2025, and up 76.0% year-over-year from $25000.0 in Q1 2025.
Summit Therapeutics (SMMT) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Summit Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $44000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 76.0% year-over-year to $44000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165000.0 (up 89.66% YoY) and the FY2025 annual result came in at $146000.0, up 64.04% from the prior year.
- Depreciation & Amortization (CF) was $44000.0 for Q1 2026 at Summit Therapeutics, up from $42000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $99000.0 in Q2 2022 and bottomed at $20000.0 in Q2 2024.
- A 5-year average of $48588.2 and a median of $42000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) plunged 70.0% — and 2025, when it soared 110.0%.
- Summit Therapeutics' Depreciation & Amortization (CF) stood at $88000.0 in 2022, then plunged by 65.91% to $30000.0 in 2023, then decreased by 26.67% to $22000.0 in 2024, then soared by 90.91% to $42000.0 in 2025, then advanced by 4.76% to $44000.0 in 2026.
- Business Quant data shows SMMT's Depreciation & Amortization (CF) at $44000.0 in Q1 2026, $42000.0 in Q4 2025, and $42000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Summit Therapeutics | 10.60 Bn | 10.00 Bn | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2023 | 30,000.00 |